

# Jennie G Jacobson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5979509/publications.pdf>

Version: 2024-02-01

25  
papers

2,076  
citations

430874

18  
h-index

580821

25  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1517  
citing authors

#	ARTICLE	IF	CITATIONS
1	Concentrated insulins: History and critical reappraisal. <i>Journal of Diabetes</i> , 2019, 11, 292-300.	1.8	18
2	Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, e66-e69.	2.8	3
3	Assessment of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain With Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 216-223.	2.2	19
4	Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects. <i>Diabetes Care</i> , 2011, 34, 2496-2501.	8.6	106
5	Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. <i>Psychiatry Research</i> , 2011, 187, 74-79.	3.3	19
6	Concomitant Oral Antihyperglycemic Agent Use and Associated Treatment Outcomes After Initiation of Insulin Therapy. <i>Endocrine Practice</i> , 2011, 17, 563-567.	2.1	10
7	Predictive Value of Early Changes in Triglycerides and Weight for Longer-Term Changes in Metabolic Measures During Olanzapine, Ziprasidone or Aripiprazole Treatment for Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 656-660.	1.4	17
8	Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: Data from a clinical study that was terminated early. <i>Schizophrenia Research</i> , 2009, 115, 370-371.	2.0	2
9	Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 278-283.	1.4	75
10	Number Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 520-528.	1.4	6
11	Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. <i>BMC Psychiatry</i> , 2008, 8, 78.	2.6	25
12	Service utilization and associated direct costs for bipolar disorder in 2004: An analysis in managed care. <i>Journal of Affective Disorders</i> , 2007, 101, 187-193.	4.1	47
13	Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1163-1171.	2.2	47
14	Linker Insertion Mutations in the Herpes Simplex Virus Type 1 UL28 Gene: Effects on UL28 Interaction with UL15 and UL33 and Identification of a Second-Site Mutation in the UL15 Gene That Suppresses a Lethal UL28 Mutation. <i>Journal of Virology</i> , 2006, 80, 12312-12323.	3.4	31
15	Fluoxetine 40â€“60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10â€“20 mg: APilot Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 207-217.	1.3	33
16	FLUOXETINE FOR DEPRESSION RELAPSE PREVENTION. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 967-968.	0.5	2
17	Fluoxetine Treatment for Prevention of Relapse of Depression in Children and Adolescents: A Double-Blind, Placebo-Controlled Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2004, 43, 1397-1405.	0.5	137
18	Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2002, 41, 1205-1215.	0.5	522

#	ARTICLE	IF	CITATIONS
19	Fluoxetine Treatment for Obsessive-Compulsive Disorder in Children and Adolescents: A Placebo-Controlled Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2001, 40, 773-779.	0.5	286
20	Importance of the Herpes Simplex Virus UL24 Gene for Productive Ganglionic Infection in Mice. <i>Virology</i> , 1998, 242, 161-169.	2.4	80
21	Synergistic effects on ganglionic herpes simplex virus infections by mutations or drugs that inhibit the viral polymerase and thymidine kinase. <i>Virology</i> , 1995, 206, 263-268.	2.4	13
22	A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. <i>Virology</i> , 1989, 173, 276-283.	2.4	296
23	Effect of an amber mutation in the herpes simplex virus thymidine kinase gene on polypeptide synthesis and stability. <i>Virology</i> , 1989, 168, 210-220.	2.4	54
24	Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. <i>Virology</i> , 1989, 168, 221-231.	2.4	76
25	VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation. <i>European Journal of Immunology</i> , 1985, 15, 502-508.	2.9	152